Silvia Sartoris

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5373965/publications.pdf

Version: 2024-02-01

430874 434195 1,202 43 18 31 citations h-index g-index papers 43 43 43 2012 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer. , 2022, 10, e003549.		22
2	A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment. Cells, 2021, 10, 2700.	4.1	25
3	The Engagement Between MDSCs and Metastases: Partners in Crime. Frontiers in Oncology, 2020, 10, 165.	2.8	50
4	Moonlighting Proteins Are Important Players in Cancer Immunology. Frontiers in Immunology, 2020, 11, 613069.	4.8	19
5	Benign acute viral myositis in African migrants: A clinical, serological, and pathological study. Muscle and Nerve, 2019, 60, 586-590.	2.2	6
6	The Endless Saga of Monocyte Diversity. Frontiers in Immunology, 2019, 10, 1786.	4.8	67
7	Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3., 2019, 7, 255.		123
8	Induction of immunosuppressive functions and NF-κB by FLIP in monocytes. Nature Communications, 2018, 9, 5193.	12.8	45
9	Hyperthermic treatment at 56â€Â°C induces tumour-specific immune protection in a mouse model of prostate cancer in both prophylactic and therapeutic immunization regimens. Vaccine, 2018, 36, 3708-3716.	3.8	11
10	Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53. Oncotarget, 2017, 8, 11809-11826.	1.8	11
11	Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. Oncotarget, 2017, 8, 86987-87001.	1.8	18
12	Feasibility of Telomerase-Specific Adoptive T-cell Therapy for B-cell Chronic Lymphocytic Leukemia and Solid Malignancies. Cancer Research, 2016, 76, 2540-2551.	0.9	25
13	Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma. Immunology, 2015, 146, 33-49.	4.4	5
14	Interfacing polymeric scaffolds with primary pancreatic ductal adenocarcinoma cells to develop 3D cancer models. Biomatter, 2014, 4, e955386.	2.6	42
15	The Emerging Immunological Role of Post-Translational Modifications by Reactive Nitrogen Species in Cancer Microenvironment. Frontiers in Immunology, 2014, 5, 69.	4.8	58
16	Efficacy Assessment of Interferon-Alpha–Engineered Mesenchymal Stromal Cells in a Mouse Plasmacytoma Model. Stem Cells and Development, 2011, 20, 709-719.	2.1	19
17	The puzzling uniqueness of the heterotrimeric G15 protein and its potential beyond hematopoiesis. Journal of Molecular Endocrinology, 2010, 44, 259-269.	2.5	27
18	IFN- \hat{I}^3 -mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine, 2010, 28, 3548-3557.	3.8	98

#	Article	IF	CITATIONS
19	Immune Regulation by Mesenchymal Stem Cells Derived from Adult Spleen and Thymus. Stem Cells and Development, 2007, 16, 797-810.	2.1	108
20	Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes. Microbes and Infection, 2006, 8, 1424-1433.	1.9	5
21	A novel cell line and xenograft model of ampulla of Vater adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 269-277.	2.8	10
22	Myelin basic protein epitopes secreted by human T cells encounter natural autoantibodies in the serum. Journal of Neuroimmunology, 2003, 141, 83-89.	2.3	2
23	Induction of an antitumour adaptive immune response elicited by tumour cells expressing de novo B7-1 mainly depends on the anatomical site of their delivery: the dose applied regulates the expansion of the response. Immunology, 2003, 110 , $474-481$.	4.4	7
24	Effects of dietary wheat germ deprivation on the immune system in Wistar rats: a pilot study. International Immunopharmacology, 2002, 2, 1495-1501.	3.8	8
25	Cell contact-dependent PMN HLA-DR and CD69 membrane expression induced by autologous mono-lymphocytes and cell lines. Inflammation, 2002, 26, 143-152.	3.8	8
26	Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones. Clinical and Experimental Immunology, 2001, 125, 391-400.	2.6	18
27	Forecasting the growth of multicell tumour spheroids: implications for the dynamic growth of solid tumours. Cell Proliferation, 2000, 33, 219-229.	5. 3	75
28	Expression of myelin basic protein (MBP) epitopes in human non-neural cells revealed by two anti-MBP IgM monoclonal antibodies. Clinical and Experimental Immunology, 2000, 122, 429-436.	2.6	6
29	Analysis of CIITA encoding AIR-1 gene promoters in insulin-dependent diabetes mellitus and rheumatoid arthritis patients from the northeast of Italy: absence of sequence variability. Human Immunology, 2000, 61, 599-604.	2.4	14
30	MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle. Microbes and Infection, 1999, 1, 871-877.	1.9	4
31	Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis. European Journal of Immunology, 1999, 29, 499-511.	2.9	22
32	Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis. European Journal of Immunology, 1999, 29, 499-511.	2.9	2
33	Divergent evolution in the mechanisms controlling major histocompatibility complex class II gene transcription in mouse and human. European Journal of Immunology, 1996, 26, 259-262.	2.9	3
34	Active suppression of the class II transactivator-encodingAIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells. European Journal of Immunology, 1996, 26, 2456-2460.	2.9	30
35	Transcriptional regulation of MHC class II genes. International Journal of Clinical and Laboratory Research, 1995, 25, 71-78.	1.0	14
36	MHC: orchestrating the immune response. Trends in Immunology, 1995, 16, 8-11.	7.5	26

3

SILVIA SARTORIS

#	Article	IF	CITATIONS
37	Evidence for a trans-acting activator function regulating the expression of the human CD5 antigen. Immunogenetics, 1994, 40, 217-221.	2.4	1
38	Physiologic target of the Air-1 trans-activator revealed by stable transfection assay. Immunogenetics, 1994, 39, 8-14.	2.4	6
39	HLA-DQB1 typing of north east Italian IDDM patients using amplified DNA, oligonucleotide probes and a rapid DNA-enzyme immunoassay (DEIA). Molecular Immunology, 1993, 30, 69-76.	2.2	11
40	CELL lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression. International Journal of Cancer, 1991, 47, 20-25.	5.1	100
41	A family of trans-acting factors with distinct regulatory functions control expression of MHC class II genes. Immunologic Research, 1990, 9, 20-33.	2.9	7
42	Sequence polymorphism of HLA-DP beta chains. Immunogenetics, 1989, 29, 346-349.	2.4	24
43	A rapid and improved method for generating cDNA libraries in plasmid and phage lambda vectors. Gene, 1987, 56, 301-307.	2.2	20